• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • Composition of Methods (COM)
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Grok 4 aids Exit
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Diabetes – A Combination Drug Therapy to induce Insulin Production by Pancreatic Beta Cells (PPAR-gamma, Leptin, ..)

Part I

Articles by LPBI Group’s Team Member

Adipocyte Derived Stroma Cells: Their Usage in Regenerative Medicine and Reprogramming into Pancreatic Beta-Like Cells

Curator: Evelina Cohn, PhD

Fat Cells Reprogrammed to Make Insulin

Curator: Larry H. Bernstein, MD, FCAP

 

Part II

Diabetes: All Drugs in Development

Curator: Stephen J Williams, PhD

 

 

Table 1. Drugs in Development1–3
Generic/Code Name Manufacturer Indication Phase
DPP-4 Inhibitors
Alogliptin/SYR-322 Takeda Type 2 diabetes NDA submitted
AMG 222/ALS2- 0426 Amgen/Servier Type 2 diabetes 2
Dutogliptin/PHX1149 Phenomix/Forest Laboratories Type 2 diabetes 3
KRP-204/N-5984 Kyorin Type 2 diabetes 2
KRP-104 Kyorin/ActivX Biosciences Type 2 diabetes 2
Linagliptin/BI-1356 Boehringer Ingelheim Type 2 diabetes 3
Melogliptin/GRC 8200 Glenmark Pharmaceuticals Type 2 diabetes 2
MP-513 Mitsubishi Tanabe Pharma Type 2 diabetes 2
PF 734200 Pfizer Type 2 diabetes 2
R1579 Roche/Chugai Type 2 diabetes 2
Saxagliptin/BMS-477118 Bristol-Myers Squibb/AstraZeneca Type 2 diabetes NDA submitted
SYR 472 Takeda Type 2 diabetes 2
TA-6666 Mitsubishi Tanabe Type 2 diabetes 2
Vildagliptin Novartis Type 2 diabetes NDA submitted
GLP-1 Analogs
Albiglutide/GSK716155 GSK Type 2 diabetes 2
AVE0010/ZP-10 Sanofi-Aventis Type 2 diabetes 3
CJC-1134-PC/PC-DAC: Exendin-4 ConjuChem Type 2 diabetes 2
Exenatide LAR Amylin/Alkermes/Lilly Type 2 diabetes 3
Liraglutide/NN2211 Novo Nordisk Type 2 diabetes NDA submitted
LY 2189265 Lilly Type 2 diabetes 3
NN9535 Novo Nordisk Type 2 diabetes 2
Taspoglutide/R1583/BIM-51077 Roche/Ipsen Type 2 diabetes 3
Biguanides
Metformin gum/buccal Generex/Fertin Pharma Type 2 diabetes 2
Thiazolidinediones/PPAR-γ Agonists
Balaglitazone/DRF-2593 Dr. Reddy’s Laboratories/Rheoscience Type 2 diabetes 3
Mitoglitazone/MDSC 0160 Metabolic Solutions Development Type 2 diabetes 2
Netoglitazone/MCC-55 Mitsubishi Tanabe/Perlegen Type 2 diabetes 2
Rivoglitazone/CS-011 Daiichi-Sankyo Type 2 diabetes 3
Other PPAR Agonists
Aleglitazar/R1439 Roche Type 2 diabetes 2
Indeglitazar Pexxikon/Wyeth Type 2 diabetes 2
INT 131/AMG131 Amgen/InteKrin Therapeutics Type 2 diabetes 2
MBX 2044 Metabolex/Ortho-McNeil Type 2 diabetes 2
Metaglidasen/MBX 102/JNJ-39659100 Metabolex/Ortho-McNeil Type 2 diabetes 2
ONO-5129 Ono Type 2 diabetes 2
PLX204/PPM-204 Plexxikon/Wyeth Type 2 diabetes 2
Selective Sodium Glucose Cotransporter Inhibitors
ASP1941 Astellas Type 2 diabetes 2
AVE2268 Sanofi-Aventis Type 2 diabetes 2
BI 10773 Boehringer Ingelheim Type 2 diabetes 2
Dapagliflozin/BMS512148 AstraZeneca/Bristol-Myers Squibb Type 2 diabetes 3
KGT-1681 GSK/Kissei Type 2 diabetes 2
Remogliflozin/189075 GSK/Kissei Type 2 diabetes 2
TA-7284 Mitsubishi Tanabe/Ortho McNeil Type 2 diabetes 2
YM543 Astellas Type 2 diabetes 2
Glinides
Mitiglinide Elixir Pharmaceuticals Type 2 diabetes 3
Insulins
Inhaled Technosphere insulin Mannkind Type 1 and type 2 diabetes 3
Insulin intranasal Bentley Type 1 and type 2 diabetes 2
Insulin intranasal MDRNA Type 2 diabetes 2
Oral HDV insulin Diasome Type 2 diabetes 2
Oral insulin spray Generex Type 1 and type 2 diabetes 3
NN1250 insulin analog for
injection		 Novo Nordisk Type 1 and type 2 diabetes 2
NN5401 insulin analog for
injection		 Novo Nordisk Type 1 and type 2 diabetes 2
Rapid-acting insulin for injection Biodel Type 1 and type 2 diabetes 3
Recombinant human hyaluroindase (rHuPH20)/insulin co-formulation for injection Halozyme Therapeutics Type 1 diabetes 2
Other Drugs in Development
Generic/Code Name Manufacturer Mechanism Indication
AJD101 Daiichi Sankyo Activates insulin signaling pathway Type 2 diabetes
AKP- 020 Akesis Vanadium compound Type 2 diabetes
AMG-108 Amgen Interleukin-1 inhibitor Type 2 diabetes
AZD6370 AstraZeneca Glucokinase activator Type 2 diabetes
Bromocriptine VeroScience Dopamine D2 receptor
agonist		 Type 2 diabetes
Canakinumab/ACZ885 Novartis Anti-interleukin-1 beta antibody Type 2 diabetes
Colestimide Mitsubishi-Tanabe Unknown Type 2 diabetes
Bezafibrate + diflunisal/ CRx-401 CombinatoRx Unknown Type 2 diabetes
DIO-902/2S,4R ketoconazole DiObex Cortisol synthesis inhibitor Type 2 diabetes
DM-71/bethanechol and N-acetyl cysteine Diamedica Unknown Type 2 diabetes
DM-83/combination of two generic compounds Diamedica Unknown Type 2 diabetes
E1 INT Transition Therapeutics Islet regeneration factor Type 1 and type 2 diabetes
Eprodisate/NC-503 Bellus Health Serum amyloid A protein inhibitor ?
Ex vivo cultured adult human mesenchymal stem cells Osiris Mesenchymal stem cell
therapy		 Type 1 diabetes
HE3286 Hollis-Eden Insulin sensitizer (NF-kappaB pathway/TLR4 receptor) Type 2 diabetes
INCB 13739 Incyte 11-beta hydroxysteroid dehydrogenase inhibitor Type 2 diabetes
INCB 19602 Incyte GPR109A receptor agonist / HM74a agonist Type 2 diabetes
INGAP peptide Kinexum Islet neogenesis associated protein Type 1 and type 2 diabetes
ISIS 113715 Isis PTP1B Type 2 diabetes
MB 07803 Metabasis/Daiichi
Sankyo		 Fructose-1,6-bisphosphatase inhibitor Type 2 diabetes
MK 0893 Merck Unknown Type 2 diabetes
MK 0941 Merck Unknown Type 2 diabetes
Otelixizumab/TRX4 GSK, Tolerx Anti-CD3 MAb Type 1 diabetes
rhGAD65/recombinant human glutamic acid decarboxylase Diamyd Therapeutics Vaccine/induces immunmotolerization Type 1 diabetes
Succinobucol/AGI 1067 AtheroGenics Antioxidant/vascular cell adhesion molecule-1 Type 2 diabetes
Tagatose Spherix Attenuates intestinal glucose absorption Type 2 diabetes
Teplizumab/MGA031/ hOKT3gamma1(Ala-Ala) Lilly/MacroGenics Anti-CD3 MAb Type 1 diabetes
TT-223 Lilly/Transition Therapeutics Gastrin analog Type 1 and type 2 diabetes

 

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,056 other subscribers

  • Recent Posts

    • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UB, Berkeley, 1983. January 31, 2026
    • 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
    • Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
    • Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
    • List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
    • Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
    • Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com January 10, 2026
    • The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr) January 8, 2026
    • 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage January 6, 2026
    • Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods January 6, 2026

  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d